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Episodes of hypoglycemia are characterized by behavioral 
and cognitive disturbance, and if untreated, can progress to 
seizure, coma, and even death.[5] Despite of the treatment 
advances in the electronic/mechanical devices and chemical 
approaches to insulin delivery, hypoglycemia still remains 
a concern, even in a closed-loop insulin delivery system.[6] 
Glucagon, a peptide hormone produced by alpha cells of the 
pancreas, works to counteract the effect of insulin and raises 
blood glucose levels (BGLs). The pancreas releases glucagon 
when BGLs are low, which acts in the liver to promote con-
version of stored glycogen into glucose that is released into 
the bloodstream.[7,8] Thus, glucagon is effective for preven-
tion and treatment of hypoglycemia, and several dual hor-
mone (insulin and glucagon) infusion pumps with continuous 
glucose monitoring systems have been developed to improve 
blood glucose control.[9,10] However, the lag in glucose feed-
back and biofouling still limit the further clinical applications 
of these electronic/mechanical devices.[2,11]
Here, we report a novel, insulin-responsive glucagon 
delivery strategy incorporating a microneedle-based trans-
dermal patch for prevention of hypoglycemic episodes during 
diabetes management. To achieve insulin-responsiveness, 
an insulin aptamer comprised of a single-stranded oligonu-
cleotide with unique secondary structure that can specifically 
bind to its target insulin[12,13] was conjugated to glucagon. 
The aptamer–glucagon conjugates (Apt–Glu) were further DOI: 10.1002/smll.201603028
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Hypoglycemia, the state of abnormally low blood glucose level, is an acute
complication of insulin and sulfonylurea therapy in diabetes management. Frequent 
insulin dosing and boluses during daily diabetes care leads to an increased risk of 
dangerously low glucose levels, which can cause behavioral and cognitive disturbance, 
seizure, coma, and even death. This study reports an insulin-responsive glucagon 
delivery method based on a microneedle (MN)-array patch for the prevention of 
hypoglycemia. The controlled release of glucagon is achieved in response to elevated 
insulin concentration by taking advantage of the specific interaction between insulin 
aptamer and target insulin. Integrating a painless MN-array patch, it is demonstrated 
that this insulin-triggered glucagon delivery device is able to prevent hypoglycemia 
following a high-dose insulin injection in a chemically induced type 1 diabetic mouse 
model.
Insulin replacement is essential for type 1 and advanced 
type 2 diabetic patients.[1,2] For patients with type 1 dia-
betes in particular, intensive insulin therapy is associated 
with improved glycemic control and decreased risk of long-
term complications.[3,4] However, frequent insulin dosing 
and boluses, either through injection or through subcuta-
neous insulin infusion, leads to an increasing risk of hypo-
glycemia, or dangerously low levels of glucose in the blood. 
bound to insulin immobilized on methacrylated hyalu-
ronic acid (m-HA) through the interaction between insulin 
aptamer and insulin. HA was chosen due to its high biocom-
patibility and biodegradability.[14] The insulin-responsive 
glucagon conjugated HA (Glu–HA) matrix can be formed 
via polymerization with crosslinkers and photoinitiator post 
UV irradiation.[15] In the presence of a high insulin concen-
tration, glucagon can be rapidly released from the HA matrix 
through the competitive binding between free insulin and 
immobilized insulin on HA. For a long-term, painless, and 
convenient treatment,[16–19] the insulin-responsive Glu–HA 
matrix was further integrated with a microneedle (MN)-array 
patch for transcutaneous administration. The MNs formed 
from Glu–HA were able to release glucagon in response 
to the elevated interstitial fluid insulin level in vascular 
and lymph capillary networks, thereby preventing the risk 
of hypoglycemia (Figure 1). Finally, we demonstrated this 
insulin-triggered glucagon delivery system plays a remark-
able role in prevention of hypoglycemia after injection of a 
high dose of insulin in a streptozotocin (STZ)-induced type 1 
diabetic mouse model.
In order to prepare insulin-responsive Glu–HA, we 
first synthesized insulin conjugated m-HA (Ins–HA) and 
insulin aptamer modified glucagon (Apt–Glu). The cova-
lent coup ling of insulin onto m-HA was 
achieved by formation of an amide bond 
between the primary amino groups of 
insulin and the carboxylic acid groups 
of the m-HA. The Apt–Glu conjugate 
was obtained from the amino-modified 
aptamer and thiolated glucagon via a 
hetero-bifunctional linker. The successful 
modification on glucagon was clearly 
identified by the matrix-assisted laser 
desorption/ionization mass spectrometry 
(Figure S1, Supporting Information). The 
bioactivity of the resulting Apt–Glu con-
jugates was confirmed upon administra-
tion on the healthy mice when compared 
to the native glucagon (Figure S2, Supporting Information). 
After coincubating Apt–Glu and Ins–HA in Tris buffer 
(50 × 10−3 m Tris–HCl, 10 × 10−3 m KCl, 100 × 10−3 m NaCl, 
pH 8.0), Apt–Glu bound to Ins–HA to form insulin-respon-
sive Glu–HA through specific interaction between the 
binding aptamer and target insulin.
Upon the addition of a crosslinker N,N′-methyleneb-
isacrylamide and a photoinitiator, Glu–HA can form a 
hydrogel by photopolymerization after UV irradiation for 
a short period of time. To assess the ability of Glu–HA to 
respond to insulin, the prepared hydrogels were incubated 
with 1× phosphate buffered saline (PBS) [137 × 10−3 m NaCl, 
2.7 × 10−3 m KCl, 10 × 10−3 m Na2HPO4, 2 × 10−3 m KH2PO4
(pH 7.4)] at increasing insulin concentrations. As presented 
in Figure 2a, the release rate of glucagon from the Glu–HA 
hydrogel was highly dependent on the concentration of 
insulin, such that the hydrogel incubated with 1 mg mL−1 
insulin showed the fastest release rate compared to those 
with 0, 0.1, and 0.5 mg mL−1 insulin. The insulin responsive-
ness of the Glu–HA hydrogel was further verified by rap-
idly changing the insulin concentration in the solution and 
measuring glucagon release rate. The Glu–HA hydrogel was 
stable in PBS buffer without insulin. When adding 1 mg mL−1 
insulin to the solution, the Glu–HA hydrogel quickly released 
glucagon (Figure 2b). We attributed this remarkable insulin-
responsive release of glucagon to the competitive binding 
between free insulin and insulin conjugated on m-HA to 
their specific aptamer on the Apt–Glu conjugate.
A MN-based transdermal delivery system was chosen 
to achieve a painless, convenient, and long-term administra-
tion.[16,17] In order to fabricate drug-loaded MN, Glu–HA, 
the crosslinker N,N′-methylenebisacrylamide and a photo-
initiator were first loaded in the tip region of a silicone mold 
of MN-array patch through centrifugation. After exposure to 
UV irradiation for 60 s, the HA matrix containing glucagon 
was formed by photo-crosslinked, which can not only avoid 
the diffusion of Glu–HA in vivo, but also enhance the stiffness 
of MNs for penetration. The prepared MNs were arranged in 
a 15 × 15 array (Figure 3a). Each MN is 300 µm in diameter 
at the base and 600 µm in height (Figure 3c). To further con-
firm the distribution of Glu–HA in the MNs, a fluorescein 
isothiocyanate (FITC)-labeled Glu–HA loaded patch was 
imaged by fluorescence microscopy. As shown in Figure 3b, 
Glu–HA was mainly located in the tips of MNs. Using a 
Figure 1. Schematic of the insulin-responsive glucagon delivery system 
based on MN-array patches.
Figure 2. a) In vitro accumulated glucagon release from the Glu–HA hydrogel in increasing 
concentrations of insulin at 37 °C. b) Self-regulated profiles of the Glu–HA hydrogel present 
the release rate of glucagon as a function of insulin concentration.
tensile compression machine, the failure force for crosslinked 
MN was determined to be 2.8 N per needle (Figure S3, Sup-
porting Information), which is sufficient to penetrate skin 
without breaking.[20] The Glu–HA loaded MNs exhibited 
similar insulin-responsive capability com-
pared to the hydrogel (Figure 3d).
Next, the in vivo insulin-responsive 
performance of Glu–HA loaded MNs 
were tested in an STZ-induced type 1 
diabetic mouse model. Prior to a subcuta-
neous injection of insulin, the drug loaded 
MN-array patch was administered on the 
dorsum of mice. The successful penetra-
tion of MNs was affirmed by the trypan 
blue staining of dorsum skin (Figure S4a, 
Supporting Information). In addition, 
the hematoxylin and eosin staining result 
showed the MN could be removed intact 
from skin (Figure S4a, Supporting Infor-
mation), indicating its minimal side effect. 
Mice were injected with a high dose of 
insulin sufficient to cause profound hypo-
glycemia and the BGLs of the treated 
mice were monitored over time. As pre-
sent in Figure 4a, the BGLs of the mice in 
control group rapidly decreased to normal 
range (<200 mg dL−1) within 0.5 h, and 
continued to decline to a hypoglycemic 
state (<70 mg dL−1).[21] The long-term 
hypoglycemia caused the death of the 
mice. By contrast, the BGLs of the mice 
with Glu–HA loaded MNs were main-
tained at 80 mg dL−1 for 2 h, and then 
slowly returned to hyperglycemia, which 
indicated the Glu–HA loaded MNs were 
able to respond to high insulin level and 
release glucagon into the regional lymph 
and capillary vessels to avoid the risk of 
hypoglycemia. As expected, the serum 
glucagon levels in mice administered 
with Glu–HA loaded MNs significantly 
increased following the increase of insulin 
concentration (Figure 4c; Figure S5, Sup-
porting Information).
To further assess the responsive-
ness and the potential for inappro-
priate release of glucagon by Glu–HA 
loaded MNs, the mice with and without 
patches were subcutaneously injected 
with a low dose of insulin. The BGLs of 
mice in both groups declined to normal 
state and began to increase 2 h postin-
jection (Figure 4b). Finally, the BGLs 
returned to hyperglycemia within the 
similar time period. The mice with MNs 
also presented reduced serum glucagon 
levels compared to those injected with 
the high dose of insulin, suggesting that 
glucagon release was directly responsive 
to serum insulin levels (Figure 4c). Finally, Glu–HA loaded 
MNs were tested on healthy mice. Unlike the free glucagon-
loaded MN, which led to rapid increase in BGLs due to the 
burst release of glucagon, the mice treated Glu–HA loaded 
Figure 3. a) A photograph of the MN-array patch. Scale bar is 1 mm. b) A fluorescence 
microscopy image of rhodamine-labeled MN loading FITC-labeled Glu–HA. Scale bar is 
500 µm. c) An SEM image of MN array. Scale bar is 200 µm. d) Self-regulated profiles of the 
Glu–HA loaded MN present the release rate of glucagon as a function of insulin concentration.
Figure 4. In vivo studies of the Glu–HA loaded MN-array patches for prevention of 
hypoglycemia. a) BLGs in STZ-induced diabetic mice with or without Glu–HA loaded 
MN after injecting a high-dose insulin (100 µg). b) BLGs of mice with or without Glu–HA 
loaded MN after injecting a low-dose insulin (20 µg). Hypoglycemic levels (<70 mg dL−1) 
were indicated by the dashed line. c) Plasma glucagon concentrations in treated mice. 
d) The blood glucose changes of healthy mice administered with Glu–HA loaded MN or free
glucagon-loaded MN.
MNs did not show significant changes in BGLs (Figure 4d), 
indicating there was little leak in Glu–HA MNs in healthy 
mice. Since HA is highly biocompatible and biodegradable, 
no significant inflammation was observed around the region 
24 h postadministration of Glu–HA MN (Figure S6, Sup-
porting Information). Collectively, the Glu–HA loaded MNs 
have capability to release glucagon in a serum insulin level 
dependent manner to prevent hypoglycemia in the insulin 
replacement therapy.
In summary, we developed an MN-array patch-based 
approach for insulin-triggered delivery of glucagon. Through 
the competitive binding between free insulin and immobi-
lized insulin on HA to insulin aptamer-modified glucagon, 
the drug-loaded HA matrix can effectively release glucagon 
under a high insulin concentration, but does not release 
glucagon without insulin. In vivo studies in a type 1 diabetic 
mouse model demonstrated that the insulin-responsive MN-
array patch was able to prevent hypoglycemia after injection 
of a high dose of insulin sufficient to cause hypoglycemia, 
while showing insignificant action in mice treated with a low 
dose of insulin. The potential translation of this glucagon 
patch would profoundly improve the health as well as the 
quality of life of type 1 and advanced type 2 diabetic patients 
by both facilitating insulin intensification with reduced risk of 
hypoglycemia and preventing morbidity and mortality from 
severe episodes of hypoglycemia. This aptamer-incorporated 
controlled release method can also be extended to engineer 
other closed-loop therapeutic delivery systems[22] to treat a 
variety of other diseases.
Experimental Section
Materials: All chemicals were purchased from Sigma-Aldrich 
unless otherwise specified and were used as received. Human 
recombinant insulin (Zn salt, 27.5 IU mg−1) was purchased from 
Life Technology. Amino modified insulin binding aptamer was 
purchased from Integrated DNA Technologies Inc. (Coralville, IA, 
USA): 5′-H2N-GGT GGT GGG GGG GGT TGG TAG GGT GTC TTC-3′.
Synthesis of Apt–Glucagon: Glucagon or FITC-labeled glucagon 
was thiolated by reacting with the Traut’s Reagent (2-iminothi-
olane, Pierce) in PBS (pH 8.0) at a molar ratio of 1:10 for 1 h at 
room temperature (RT). Excess Traut’s Reagent was removed using 
a centrifugal filter d evice ( molecular w eight c ut-off = 3  k Da). I n 
the meantime, amino modified i nsulin a ptamer w as m ixed w ith 
sulfosuccinimidyl-4-(N-maleimidomethyl)- cyclohexane-1-carbox-
ylate (Sulfo-SMCC, Pierce) in PBS (pH = 7.4) at a molar ratio of 1:5 
for 0.5 h at RT. The activated aptamer was purified using a Nap-5 
column. Finally, the purified aptamer and glucagon-SH were mixed 
in PBS (pH 8.0) at a molar ratio of glucagon:aptamer = 1:2. After 
24 h reaction at 4 °C, the obtained Apt–Glu was purified using a 
Nap-5 column, and stored at 4 °C until use.
Synthesis of Ins–HA: 60 mg of m-HA was dissolved in water, to 
which 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (0.19 g) and 
N-hydroxysuccinimide (0.13 g) were added and stirred for 15 min 
at RT. Then insulin (30 mg) was added to the mixture and reacted 
at 4 °C for 24 h. The reaction solution was thoroughly dialyzed 
against DI water for 1 d. Finally, Ins–HA was obtained by lyophiliza-
tion. Mn = 431 475 g mol−1.
Preparation of Glu–HA Hydrogel: Crosslinker N,N′-methylen-
ebisacrylamide (w/v = 2%) and photoinitiator (Irgacure 2959, 
w/v = 0.5%) were mixed in Glu–HA solution. After UV irradia-
tion (wavelength: 365 nm) for 60 s, the mixture underwent the 
crosslinking polymerization to form the hydrogel.
In Vitro Release Studies: After preparation of the FITC-labeled 
Glu–HA hydrogel, various PBS solutions with 0, 0.1, 0.5, and 
1 mg mL−1 insulin were added to each tube and incubated at 37 °C 
on an orbital shaker. At predetermined time points, the sample 
was centrifuged (8000 rpm, 30 s) and 100 µL of the supernatant 
was removed for analysis by measuring the emission intensity of 
FITC at 519 nm with the excitation wavelength at 495 nm.
In Vivo Studies Using STZ-Induced Diabetic Mice: The in vivo 
performance of MN-array patches was evaluated on STZ-induced 
adult diabetic mice (male C57B6, Jackson Lab, USA). The animal 
study protocol was approved by the Institutional Animal Care and 
Use Committee at North Carolina State University and University of 
North Carolina at Chapel Hill. The plasma-equivalent glucose was 
measured from tail vein blood samples (≈3 µL) of mice using the 
Clarity GL2Plus glucose meter (Clarity Diagnostics, Boca Raton, 
Florida). Mouse glucose levels were monitored for two days before 
administration, and all mice were fasted overnight before admin-
istration. Five mice for each group were selected to be transcuta-
neously treated with blank MNs containing only m-HA or Glu–HA 
loaded MNs. Afterward, a high-dose insulin (100 µg) or a low-dose 
insulin (20 µg) was subcutaneously injected into each mouse. The 
glucose levels of each mouse were monitored over time. In order 
to measure the plasma glucagon concentration in vivo, 25 µL of 
blood sample was drawn from the tail vein of mice at indicated 
time points. The serum was isolated and stored at −20 °C until 
assay. The plasma glucagon concentration was measured using 
Human Glucagon ELISA Kit (Thermo Scientific).
Statistical Analysis: All results presented are mean ± s.d. Sta-
tistical analysis was performed using Student’s t-test or ANOVA 
test. With a P value <0.05, the differences between experimental 
groups and control groups were considered statistic.
Supporting Information
Supporting Information is available from the Wiley Online Library 
or from the author.
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